Fausto Petrelli1, Tiziana Comito2, Antonio Ghidini3, Valter Torri4, Marta Scorsetti2, Sandro Barni5. 1. Oncology Unit, Department of Oncology, ASST Bergamo Ovest, Treviglio, Italy. Electronic address: faupe@libero.it. 2. Department of Radiosurgery and Radiotherapy, Istituto Clinico Humanitas Cancer Center and Research Hospital, Milan, Italy. 3. Oncology Unit, Igea Hospital, Milan, Italy. 4. Department of Biomedical Sciences, Humanitas University and Radiotherapy and Radiosurgery Department-Humanitas Research Hospital, Milan, Italy. 5. Oncology Unit, Department of Oncology, ASST Bergamo Ovest, Treviglio, Italy.
Abstract
PURPOSE: Although surgery is the standard of care for resectable pancreatic cancer (PC), standard-dose chemoradiation therapy and chemotherapy alone are suitable for patients with unresectable disease. Stereotactic body radiation therapy (SBRT) is an alternative, focused local therapy that delivers high radiation doses within a few fractions to the cancer, sparing the surrounding critical tissue. We performed a systematic review and pooled analysis of published trials to evaluate the efficacy and safety of this emerging treatment modality. METHODS AND MATERIALS: We searched the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, SCOPUS, the Web of Science, and CINAHL for publications regarding SBRT for locally advanced PC. The 1-year overall survival (OS) rate was the primary endpoint, and the median OS, 2-year OS rate, 1-year locoregional control (LRC) rate, and grade 3 to 4 toxicities were the secondary endpoints. A multivariate random-effects meta-analysis was performed to calculate the aggregated OS rates at 1 and 2 years and the 1-year LRC rate. RESULTS: A total of 19 studies, encompassing 1009 patients, were included in the present analysis. The pooled 1-year OS was 51.6% in 13 trials with data available. The median OS ranged from 5.7 to 47 months (median 17). The LRC rate at 1 year was 72.3%. Overall, the occurrence of severe adverse events did not exceed 10%. LRC appeared to correlate with the total SBRT dose and the number of fractions. CONCLUSIONS: The advantages of SBRT in terms of treatment time, satisfactory OS, and LRC indicate that it is an effective option for inoperable PC. However, a definitive validation of this treatment modality in large randomized studies is required, owing to the nonrandomized nature of the included studies and the limitations of small single-center series that include mixed populations.
PURPOSE: Although surgery is the standard of care for resectable pancreatic cancer (PC), standard-dose chemoradiation therapy and chemotherapy alone are suitable for patients with unresectable disease. Stereotactic body radiation therapy (SBRT) is an alternative, focused local therapy that delivers high radiation doses within a few fractions to the cancer, sparing the surrounding critical tissue. We performed a systematic review and pooled analysis of published trials to evaluate the efficacy and safety of this emerging treatment modality. METHODS AND MATERIALS: We searched the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, SCOPUS, the Web of Science, and CINAHL for publications regarding SBRT for locally advanced PC. The 1-year overall survival (OS) rate was the primary endpoint, and the median OS, 2-year OS rate, 1-year locoregional control (LRC) rate, and grade 3 to 4 toxicities were the secondary endpoints. A multivariate random-effects meta-analysis was performed to calculate the aggregated OS rates at 1 and 2 years and the 1-year LRC rate. RESULTS: A total of 19 studies, encompassing 1009 patients, were included in the present analysis. The pooled 1-year OS was 51.6% in 13 trials with data available. The median OS ranged from 5.7 to 47 months (median 17). The LRC rate at 1 year was 72.3%. Overall, the occurrence of severe adverse events did not exceed 10%. LRC appeared to correlate with the total SBRT dose and the number of fractions. CONCLUSIONS: The advantages of SBRT in terms of treatment time, satisfactory OS, and LRC indicate that it is an effective option for inoperable PC. However, a definitive validation of this treatment modality in large randomized studies is required, owing to the nonrandomized nature of the included studies and the limitations of small single-center series that include mixed populations.
Authors: Timothy D Malouff; Danushka Seneviratne; William C Stross; Stephen Ko; Katherine Tzou; Daniel M Trifiletti; Laura A Vallow Journal: J Radiosurg SBRT Date: 2020
Authors: Chang-Lung Lee; Patrick Oh; Eric S Xu; Yan Ma; Yongbaek Kim; Andrea R Daniel; David G Kirsch Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-26 Impact factor: 7.038
Authors: Chi Lin; Vivek Verma; Audrey Lazenby; Quan P Ly; Lyudmyla D Berim; James K Schwarz; Madi Madiyalakan; Christopher F Nicodemus; Michael A Hollingsworth; Jane L Meza; Chandrakanth Are; James Padussis; Jean L Grem Journal: Am J Clin Oncol Date: 2019-10 Impact factor: 2.339
Authors: Sung Jun Ma; Lucas M Serra; Austin J Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J Iovoli; Kavitha M Prezzano; Gregory M Hermann; Han Yu; Anurag K Singh Journal: J Radiother Pract Date: 2021-04-14
Authors: Jian Ye; Bradley N Mills; Tony Zhao; Booyeon J Han; Joseph D Murphy; Ankit P Patel; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber Journal: Cancer Immunol Res Date: 2019-11-12 Impact factor: 11.151
Authors: Xianjin Dai; Yang Lei; Jacob Wynne; James Janopaul-Naylor; Tonghe Wang; Justin Roper; Walter J Curran; Tian Liu; Pretesh Patel; Xiaofeng Yang Journal: Med Phys Date: 2021-10-13 Impact factor: 4.071